Genocea to Host KOL Symposium Highlighting GEN-011’s Potential to Transform T cell Therapy for Solid Tumors
Genocea management will highlight the potential for GEN-011 to become a best-in-class adoptive T cell therapy. GEN-011 was designed to improve upon TIL therapy. Using the company’s proprietary ATLASTM platform to select neoantigens and T cells derived from peripheral blood, Genocea believes GEN-011 may deliver greater efficacy through more active and longer-lasting T cells specific for the tumor than possible through other approaches. Genocea has also established a robust, scalable manufacturing process to simplify and expand cancer patient access to therapy.
The event will also feature
“Through GEN-011, Genocea is creating an entirely new category of T cell therapy,” said
Webcast & Conference Call Information
Interested participants may access the conference call by dialing (323) 794-2597 (domestic) or (323) 701-0218 (international) and referring to conference ID number 6118728. For those who are unable to listen in during the event, a replay of the call will be available here.
A live webcast of the KOL event can also be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. To ask a question during the live Q&A, please submit your question to email@example.com. A replay of the webcast will be archived for 30 days following the presentation.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and expect preliminary clinical results in the third quarter of 2020, and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood, for which we intend to file an Investigational New Drug Application in the second quarter of 2020. To learn more, please visit www.genocea.com.
This press release includes forward-looking statements, including statements relating to GEN-009 and GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended
Source: Genocea Biosciences, Inc.